A TikTok user sharing their week 1 experience with Zepbound (tirzepatide) or Wegovy (semaglutide) has got nearly 40,000 views, with hashtags suggesting medication anxiety and dislike. While we can't see the specific content, the hashtags tell a familiar story about GLP-1 medication experiences.
What does this video likely show?
Based on the hashtags including "week1," "ihatethis," and "medicationanxiety," this appears to document early-stage side effects from either Zepbound or Wegovy. The creator seems to be experiencing the common initial adjustment period that affects most people starting GLP-1 medications.
Week 1 reactions are extremely common with these drugs. In the SURPASS-1 trial (Rosenstock et al., Lancet, 2021), 84% of tirzepatide users experienced at least one gastrointestinal side effect. For semaglutide, the STEP 1 trial (Wilding et al., NEJM, 2021) found that 74.2% reported nausea during the study period.
The inclusion of CVS/CVS Caremark hashtags suggests insurance or pharmacy-related frustrations, which is incredibly common with these medications that can cost over $1,000 monthly without coverage.
Are week 1 struggles actually normal?
Yes, and the data backs this up completely. The creator's apparent distress, while unpleasant, reflects the typical medication experience rather than anything unusual or concerning.
Nausea hits 44% of people taking 2.4mg semaglutide and up to 12% of those on the 0.25mg starting dose, according to Wegovy prescribing information. For tirzepatide, nausea affects 12-22% of users depending on the dose, with the 2.5mg starting dose being relatively well-tolerated.
Most side effects peak in the first few weeks then improve significantly. In clinical trials, only 4.3% of semaglutide users and 4.3-7.1% of tirzepatide users discontinued due to gastrointestinal issues, meaning the vast majority push through the initial period successfully.
What won't doctors always tell you upfront?
Many healthcare providers underplay just how miserable the first few weeks can feel, even when side effects are "normal" and not dangerous. The clinical trial language of "mild to moderate nausea" doesn't capture the reality of feeling genuinely sick.
The medication anxiety hashtag points to another under-discussed issue. These aren't casual diet pills. They're powerful medications that change how your brain responds to food, which can feel psychologically unsettling even when working exactly as intended.
Insurance battles are also the norm, not the exception. A 2023 KFF analysis found that 72% of employer health plans exclude GLP-1 medications for weight management, making CVS Caremark denials extremely common regardless of medical necessity.
Does the misery actually lead anywhere good?
The clinical data says yes, but only for people who can tolerate the adjustment period. The STEP 1 trial showed 14.9% average weight loss at 68 weeks with semaglutide, while SURPASS-1 found 15.0% loss with the highest tirzepatide dose.
However, these impressive numbers come with a major caveat. They represent people who completed the full study period, not everyone who started the medication. Real-world discontinuation rates are higher than clinical trials suggest.
The creator's week 1 experience, awful as it may feel, doesn't predict their long-term success or failure. Most people who stick with GLP-1 medications find side effects improve substantially by week 4-6, though some persistent effects like reduced appetite continue indefinitely.